Ad
related to: lancet neurology instructions for authors and agents free
Search results
Results from the WOW.Com Content Network
This article about a neurology journal is a stub. You can help Wikipedia by expanding it. See tips for writing articles about academic journals. Further suggestions might be found on the article's talk page.
Becker-Barroso joined in the editorial department of Lancet Neurology in 2005 [1] before becoming the editor-in-chief of in 2012. [3] Selected publications.
The three established speciality journals (The Lancet Neurology, The Lancet Oncology, and The Lancet Infectious Diseases) have built up strong reputations in their medical speciality. According to the Journal Citation Reports , The Lancet Oncology has a 2021 impact factor of 54.433, The Lancet Neurology has 59.935, and The Lancet Infectious ...
The hallmark symptom of LATE is a progressive memory loss that predominantly affects short-term and episodic memory. [1] This impairment is often severe enough to interfere with daily functioning and usually remains the chief neurologic deficit, unlike other types of dementia in which non-memory cognitive domains and behavioral changes might be noted earlier or more prominently. [1]
Richard Charles Horton OBE FRCPCH FMedSci (born 29 December 1961) is editor-in-chief of The Lancet, a United Kingdom–based medical journal.He is an honorary professor at the London School of Hygiene and Tropical Medicine, University College London, and the University of Oslo.
Hair loss in men is common, and a quick Google search reveals all sorts of options for reducing and reversing thinning hair — topical minoxidil, hair transplant surgery, serums, and even ...
Posterior reversible encephalopathy syndrome; Other names: Reversible posterior leukoencephalopathy syndrome (RPLS) Posterior reversible encephalopathy syndrome visible on magnetic resonance imaging as multiple cortico-subcortical areas of T2-weighted hyperintense (white) signal involving the occipital and parietal lobes bilaterally and pons.
In 2021, Dr. Kopjar was a co-author on a publication in The Lancet Neurology which highlighted the findings of a multi-center, Phase 3 trial that was conducted to research the drug riluzole for the treatment of cervical spondylotic myelopathy. [21]
Ad
related to: lancet neurology instructions for authors and agents free